Welcome to our dedicated page for Definium Therapeutics news (Ticker: DFTX), a resource for investors and traders seeking the latest updates and insights on Definium Therapeutics stock.
Definium Therapeutics, Inc. develops investigational therapeutics for psychiatric and neurological disorders. The company’s news centers on DT120 ODT (lysergide tartrate), its lead Phase 3 program for generalized anxiety disorder and major depressive disorder, along with clinical-trial progress, pre-commercial planning, and updates on the treatment landscape for mood and anxiety disorders.
Recurring announcements also include quarterly and annual financial results, investor and analyst events, research publications related to generalized anxiety disorder, and public-company compensation actions such as Nasdaq inducement grants for new employees.
Definium Therapeutics (NASDAQ: DFTX) granted inducement stock options to three newly hired non-executive employees, covering an aggregate of 88,900 common shares, with an effective grant date of August 31, 2026. The exercise price equals the closing price of Definium’s common shares on the grant date.
According to Definium, the options vest over four years: 25% on the first anniversary and the remaining 75% in substantially equal monthly installments over the following three years, subject to continued employment. The grants were approved by the Compensation Committee on August 28, 2026 under NASDAQ Rule 5635(c)(4) and issued pursuant to the company’s 2026 Inducement Plan.
Definium Therapeutics (Nasdaq: DFTX) announced that its management will participate in several upcoming investor events. On September 1, 2026, the company will join a Stifel-hosted virtual fireside chat focused on positive topline Phase 3 Voyage results for DT120 ODT in generalized anxiety disorder (GAD) and expectations for the Phase 3 Panorama topline readout. Definium will also present at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 and attend the Leerink Partners Biopharma Summit from September 23–25, 2026. Audio webcasts and replays of available presentations will be posted on Definium’s investor relations website for up to 90 days after each event.
Definium Therapeutics (NASDAQ: DFTX) announced that it has granted inducement equity awards to two newly hired non-executive employees. The awards consist of options to purchase an aggregate of 32,900 common shares, with an exercise price equal to the closing price of Definium’s common shares on the August 17, 2026 grant date.
The stock options will vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in substantially equal monthly installments over the following three years, subject to continued employment. According to the company, the options were approved by the Compensation Committee on August 14, 2026 as material inducements to employment under NASDAQ Rule 5635(c)(4) and were issued under Definium’s 2026 Inducement Plan.
Definium Therapeutics (Nasdaq: DFTX) reported positive topline results from Voyage, its first Phase 3 study of single-dose DT120 (lysergide) ODT 100 µg in adults with generalized anxiety disorder (GAD). Voyage met the primary endpoint, with a Week 12 HAM-A LS mean change of -11.6 for DT120 versus -6.2 for placebo, a placebo-adjusted difference of -5.4 points (p<0.0001; Cohen’s d=0.81).
All key secondary endpoints were also met, including improvements in CGI-S at Week 12 and early effects by Day 2 and Week 1. At Week 12, HAM-A response (≥50%) was 43% for DT120 versus 16% for placebo, and remission (≤7) was 14% versus 4%. DT120 ODT was generally well tolerated, with mild to moderate, transient adverse events, no new safety signals, and no suicidality signal. Voyage enrolled 214 adults across approximately 35 U.S. sites, and is one of two pivotal Phase 3 GAD studies, alongside the ongoing Panorama trial.
Definium Therapeutics (NASDAQ: DFTX) reported second quarter 2026 results, highlighted by positive topline data from the Phase 3 Emerge study of DT120 ODT in major depressive disorder. In 149 patients, DT120 ODT 100 µg met the primary and all key secondary endpoints with high statistical significance, delivering an 8.1-point placebo-adjusted MADRS improvement at Week 6 and 7.3-point improvement at Week 12, and was generally well tolerated with no serious adverse events or suicidality signal.
The company completed enrollment in two Phase 3 GAD trials (Voyage, 214 patients; Panorama, 245 patients) with topline data expected August and September 2026, initiated the Phase 3 Ascend MDD trial, and plans a Phase 3 PTSD trial Haven in 2027. Definium closed an underwritten offering of 23.7 million shares for $805 million in gross proceeds, ending June 30, 2026 with approximately $1.1 billion in cash, cash equivalents and investments, which it believes will fund operations into 2030. Q2 R&D and G&A expenses rose to $48.7 million and $26.4 million, respectively, and net loss widened to $159.0 million, driven largely by an $86.2 million non-cash increase in warrant liabilities.
Definium Therapeutics (NASDAQ: DFTX) announced inducement equity grants to six newly hired non-executive employees, consisting of options to purchase an aggregate of 115,600 common shares, with effective grant dates of August 3, 2026.
According to Definium, the stock options have an exercise price equal to the closing price of its common shares on the grant date. They vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in substantially equal monthly installments over the following three years, subject to continued employment. The grants were approved by the Compensation Committee on August 2, 2026 as material inducements to employment under NASDAQ Rule 5635(c)(4) and were issued under the company’s 2026 Inducement Plan.
Definium Therapeutics (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company focused on therapies for psychiatric and neurological disorders, announced it will host a webcast at 4:30 p.m. EDT on Thursday, August 6, 2026.
According to the company, the event will cover second quarter 2026 financial results for the period ended June 30, 2026 and recent business highlights. Investors can access a live webcast via an online registration link, with a replay available in the Investor Relations section of the company’s website (ir.definiumtx.com) for at least 30 days. Participants are advised to join the webcast 15 minutes early.
Definium Therapeutics (NASDAQ: DFTX) announced inducement equity grants to two newly hired non-executive employees, consisting of options to purchase an aggregate of 30,330 common shares, with an effective grant date of July 20, 2026.
The stock options have an exercise price equal to the closing price of Definium’s common shares on the grant date. Vesting occurs over four years: 25% after one year and the remaining 75% in substantially equal monthly installments over the following three years, subject to continued employment. According to Definium, the grants were approved by the Compensation Committee on July 15, 2026 as material inducements to employment under NASDAQ Rule 5635(c)(4) and issued pursuant to the company’s 2026 Inducement Plan.
Definium Therapeutics (NASDAQ: DFTX) announced the July 16, 2026 launch of Wired for Worry, a disease education initiative for healthcare providers focused on generalized anxiety disorder (GAD). The program offers interactive clinical resources on GAD symptoms, assessment, disease burden, and neurobiology, emphasizing evidence-based education.
According to Definium Therapeutics, Wired for Worry highlights research on dysregulated brain circuitry in GAD and promotes consistent use of the GAD-7 screening scale to improve patient identification and outcomes. The company plans to expand the platform over time with additional educational content and coverage of other psychiatric disorders.
Definium Therapeutics (Nasdaq: DFTX) reported results from a large U.S. healthcare claims study on treatment patterns in newly diagnosed and established patients with generalized anxiety disorder (GAD), published in CNS Spectrums. The analysis examined pharmacotherapy use, discontinuation, switching, and treatment progression versus guideline-recommended treatment durations.
The study found high rates of discontinuation and switching, rapid treatment changes, and prolonged gaps in care. According to Definium Therapeutics, many patients stopped or modified initial therapy well before the recommended 6–12 months, and over half of newly diagnosed patients who discontinued did not restart during follow-up, underscoring substantial unmet need in GAD.